TESAMORELIN
Tesamorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to increase the body’s natural production of growth hormone. It is an FDA-approved medication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy and has also been studied for its effects on body composition, metabolism and other health outcomes.
TESAMORELIN — QUICK SUMMARY
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), a hormone involved in signalling the pituitary gland to release growth hormone. Rather than supplying growth hormone directly, tesamorelin stimulates the body’s own growth hormone secretion, which in turn increases downstream IGF-1 activity.
Tesamorelin has been studied extensively in adults with HIV-associated lipodystrophy, particularly for its ability to reduce visceral adipose tissue — the fat stored deeper within the abdomen around the internal organs.
In the United States, tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved as a general weight-loss medication.
Outside its approved medical use, tesamorelin has attracted interest in fitness and body-composition communities because of its effects on visceral fat and the growth hormone/IGF-1 pathway. However, evidence from its approved patient population should not automatically be assumed to produce the same results in healthy athletes or bodybuilders.
Tesamorelin is not a GLP-1 medication such as semaglutide or tirzepatide. It works through the growth hormone-releasing hormone pathway rather than primarily reducing appetite.
Tesamorelin Research & Evidence
Tesamorelin has considerably more human clinical research behind it than many peptides discussed in fitness and research communities. Much of this evidence, however, comes from people living with HIV who developed excess visceral abdominal fat.
Visceral abdominal fat
Reduction in visceral adipose tissue is the best-established body-composition effect of tesamorelin. Randomised controlled trials have consistently reported reductions in visceral abdominal fat compared with placebo.
Clinical trials have reported reductions in visceral fat in the region of approximately 15–18% in treated groups, although individual responses vary. Longer-term research found that reductions could be maintained while treatment continued, but that the effect did not necessarily persist after treatment was stopped.
Body composition
Tesamorelin appears to affect visceral fat differently from ordinary weight-loss treatments. Studies have found reductions in central or visceral fat without equivalent reductions in subcutaneous fat.
This distinction is one reason tesamorelin has attracted interest among physique-focused users. It should not, however, be interpreted as evidence that tesamorelin is an established fat-loss or bodybuilding treatment for otherwise healthy people.
Growth hormone and IGF-1
By activating GHRH receptors in the pituitary gland, tesamorelin increases endogenous growth hormone secretion. This subsequently increases circulating IGF-1.
Because IGF-1 can rise substantially, monitoring IGF-1 is an important consideration in clinical use.
Liver fat and metabolic research
Research has also examined tesamorelin’s effects on liver fat and metabolic health. A randomised study in adults with HIV-associated abdominal fat found reductions in both visceral adipose tissue and liver fat compared with placebo.
More recent analyses continue to support an effect on visceral fat and other body-composition measures, although the relevance of these findings outside the populations studied remains less certain.
Safety and side effects
Clinical use of tesamorelin can produce adverse effects. Reported concerns include injection-site reactions, fluid retention, joint or muscle discomfort, hypersensitivity reactions, increases in IGF-1 and changes in glucose regulation.
The U.S. prescribing information also contains important precautions relating to malignancy, elevated IGF-1, glucose intolerance or diabetes, fluid retention and hypersensitivity. Tesamorelin is not appropriate for everyone and medical suitability depends on the individual.
Human randomised controlled trials are available. The strongest evidence relates to HIV-associated visceral abdominal fat rather than recreational physique enhancement or general obesity treatment.
Real Experiences
Search real-world Tesamorelin experiences collected from Reddit, YouTube and other online communities. These reports are anecdotal experiences and may involve other compounds, diet or training changes.
These are individual user reports collected from third-party sources. They are presented as experiences rather than proof of cause and effect. Use the original-source link to read the surrounding discussion and context.
Independent Testing
Supp Science independently purchases products and commissions third-party laboratory testing. The results below are from tests commissioned by us — not certificates supplied by the seller.
Want a product or supplier tested? Request a test →LOGO
LOGO
LOGO
LOGO
Questions & Answers
Find answers or ask your own question.
Tesamorelin stimulates the pituitary gland to release endogenous growth hormone. This increases downstream IGF-1 activity. Its best-established clinical effect is a reduction in excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Human clinical trials have shown significant reductions in visceral abdominal fat. Visceral fat is the deeper fat surrounding the abdominal organs and is different from the subcutaneous fat directly beneath the skin.
No. Tesamorelin’s U.S. approval is specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The FDA prescribing information states that it is not indicated for general weight-loss management.
No. Growth hormone supplies GH directly. Tesamorelin is a GHRH analogue that signals the pituitary gland to increase the body’s own growth hormone secretion.
Yes. Increased growth hormone secretion leads to increased IGF-1, and rises in IGF-1 have been documented in clinical trials. This is part of tesamorelin’s biological activity and also one of the parameters considered during medical monitoring.
Tesamorelin is not approved as a muscle-building treatment. Some research has reported changes in skeletal muscle measures in people who responded to tesamorelin with substantial reductions in visceral fat, but evidence is insufficient to treat tesamorelin as an established muscle-building therapy in healthy athletes.
No. Tesamorelin works through the GHRH-growth hormone pathway. Semaglutide and tirzepatide work primarily through incretin pathways such as GLP-1 and, in the case of tirzepatide, GIP. They are different classes of compounds with different mechanisms and approved uses.
Tesamorelin does not have the same approved therapeutic status in Australia as it does in the United States. In Australia, peptide products used for therapeutic purposes are regulated by the Therapeutic Goods Administration, and unapproved therapeutic goods are subject to specific access and importation rules.
Clinical trials and prescribing information report effects including injection-site reactions, joint or muscle symptoms, peripheral swelling, hypersensitivity reactions and changes in glucose regulation. Tesamorelin can also substantially increase IGF-1.
Clinical research suggests that the reduction in visceral fat is not necessarily permanent. Longer-term trials found that improvements were maintained during treatment but tended to diminish after treatment was discontinued.
Ask us instead and we’ll get back to you.
Ask a question →Can’t find your answer?
Ask us and we’ll get back to you.
We’ll take a look and get back to you by email.
Community Discussions
See what people are saying about Tesamorelin.
Tesamorelin and visceral fat results
I’m about 8 weeks in now and the main thing I’ve noticed is my waist hasn’t changed much but my stomach looks noticeably different. I wasn’t expecting much until I got further into it, so I’m interested to see what happens over the next few weeks.
Tesamorelin vs CJC/Ipamorelin
I’ve tried both and personally found them pretty different. Tesamorelin seemed like it took a lot longer before I noticed anything, whereas CJC and Ipamorelin felt different from the start. Curious if anyone else has compared them.
How long before you noticed anything from Tesamorelin?
For people who’ve used it for a decent amount of time, when did you actually start noticing a difference? I’m seeing studies running for months but most discussions online seem to focus on much shorter periods.
Medical Literature
Research findings summarised in plain English.
Tesamorelin randomised controlled trial meta-analysis
A pooled analysis of five randomised trials found significant reductions in visceral adipose tissue, trunk fat, waist circumference and hepatic fat measures among tesamorelin-treated participants.
Visceral fat reduction and skeletal muscle changes
Among participants who experienced clinically significant visceral-fat reduction, tesamorelin was associated with increases in skeletal muscle area and density. The authors noted that further study is required.
Effect of tesamorelin on visceral fat and liver fat
Researchers reported significant reductions in visceral adipose tissue and liver fat compared with placebo over six months.
Effects of tesamorelin on abdominal fat in HIV-associated lipodystrophy
Tesamorelin reduced visceral abdominal fat and maintained the reduction during continued therapy, while largely preserving abdominal subcutaneous fat.
Long-term safety and effects of tesamorelin
Reductions in visceral adipose tissue were sustained during treatment for up to 52 weeks. The research also found that the visceral-fat effect did not persist after treatment was discontinued.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Daily tesamorelin treatment for 26 weeks was associated with reduced visceral fat and improvements in lipid measures in adults with HIV-associated central fat accumulation.
Current U.S. prescribing information — EGRIFTA WR
The official prescribing information covers tesamorelin’s approved indication, contraindications, warnings, adverse reactions and clinical study data.